Cure8 research brief
Why This Matters
Highlights variation in physician confidence to start biologics in Pakistan and links between training exposure and use of advanced therapies; points to access, cost, and infection-screening as practical barriers that can affect care for people with IBD.
Who Should Pay Attention
Clinicians treating IBD, IBD trainers and program directors, health system planners, and patient advocates in Pakistan and similar settings.
Study Snapshot
What To Know
This paper reports survey results (not a clinical trial). Most respondents were formally trained gastroenterologists. Physicians with overseas training were more likely to feel confident initiating biologics for both ulcerative colitis and Crohn’s disease.
Higher confidence was associated with earlier use of advanced therapies (including anti-TNF agents and oral targeted therapies).
Commonly reported barriers included infection-screening challenges, medication cost, and limited access, and the authors suggest strengthening IBD-focused training and addressing systemic barriers to improve guideline-concordant care.
Keep In Mind
Survey-based results reflect self-report and associations; they do not provide direct evidence on patient outcomes or efficacy. Findings are grounded in the article abstract and full-text survey report.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.